REQUEST A DEMO
Total
USD $0.00
Search more companies

Astellas Pharma Singapore Pte. Ltd. (Singapore)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Astellas Pharma Singapore Pte. Ltd. Profile Updated: August 29, 2019
Buy our report for this company USD 19.99 Most recent financial data: 2018 Available in: English Download a sample report

Astellas Pharma Singapore Pte. Ltd. is engaged in supply and distribution of pharmaceutical products and medicines used in urology, transplantation, and oncology. The company operates as a subsidiary of Astellas Pharma Inc. in Japan.

Headquarters
6 Temasek Boulevard #26-03/05 Suntec Tower Four Singapore 038986
Singapore; Singapore; Postal Code: 038986

Contact Details: Purchase the Astellas Pharma Singapore Pte. Ltd. report to view the information.

Basic Information
Outstanding Shares:
Purchase the Astellas Pharma Singapore Pte. Ltd. report to view the information.
Registered Capital:
Purchase the Astellas Pharma Singapore Pte. Ltd. report to view the information.
Financial Auditors:
Purchase the Astellas Pharma Singapore Pte. Ltd. report to view the information.
Incorporation Date:
July 01, 2013
Key Executives
Purchase this report to view the information.
Chairman/Director
Purchase this report to view the information.
Chairman/Director
Purchase this report to view the information.
Chairman/Managing Director
Purchase this report to view the information.
Secretary
Purchase this report to view the information.
Secretary
Ownership Details
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Astellas Pharma Singapore Pte. Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency SGD. Absolute financial data is included in the purchased report.
Total operating revenue
11.04%
Net Profit (Loss) for the Period
7.31%
Total assets
42.59%
Total equity
29.14%
Return on Equity (ROE)
-4.59%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?